Blueprint Medicines has begun the enrolment and dosing of patients in its Phase I clinical trial of BLU-667 to treat advanced solid tumours with rational emotive therapy (RET) alteration such as non-small-cell lung cancer (NSCLC) and medullary thyroid cancer (MTC).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BLU-667 is an oral, potent and selective inhibitor currently being developed to target RET mutations, fusions and predicted resistance mutants.

Designed to enrol around 115 patients at various sites in the US and the EU, the Phase I trial will evaluate the safety and tolerability of BLU-667 in multiple ascending doses to determine a maximum tolerated dose (MTD).

Blueprint Medicines chief executive officer Jeff Albers said: "By rapidly initiating a clinical trial for our potent and selective RET inhibitor BLU-667, we have successfully achieved a key 2017 milestone.

See Also:

"BLU-667 has a unique product profile differentiated from our other clinical-stage programmes by its potential to address predicted resistance mutations that may arise.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"By rapidly initiating a clinical trial for our potent and selective RET inhibitor BLU-667, we have successfully achieved a key 2017 milestone."

"With BLU-667 enrolment underway, we are further increasing our diversified pipeline of potent, highly selective investigational medicines that target specific disease drivers in genomically defined patient populations."

The firm intends to further initiate expansion cohorts for NSCLC patients with a RET rearrangement, MTC patients and patients with other RET-altered solid tumours.

Approximately 35 patients will be enrolled during the dose escalation part of the trial, while the expansion cohorts will see an enrolment of 80 patients.

The trial's secondary objectives include assessment of pharmacokinetic profile, RET gene status in plasma and tumour tissue, characterising the pharmacodynamic effects and establishing the response rate.

Image: Micrograph of medullary thyroid carcinoma. Photo: courtesy of Nephron/Wikipedia.